What Biosteron Treats: Main Uses and Benefits

Biosteron is used for managing the symptoms of Genitourinary Syndrome of Menopause (GSM), specifically treating Vulvar and Vaginal Atrophy (VVA) in postmenopausal women. The medication is relevant in conditions characterized by periods of heightened symptoms of this nature, and its therapeutic scope includes persistent vaginal dryness, soreness, burning, and moderate to severe dyspareunia (painful intercourse). This treatment is applied across domains where additional symptomatic support is needed.

The treatment is commonly used to help with symptoms that create noticeable physical strain, and it may assist with maintaining functional stability. This supportive therapy contributes to easing the overall symptom load and helps improve day-to-day comfort. Patients often seek this therapy when they experience significant discomfort interfering with daily life.

---

Quick Fact: Therapeutic Scope

Biosteron is specifically employed to help with the symptom of moderate to severe dyspareunia, supporting improved sexual comfort and assisting patients with maintaining functional stability during episodes of heightened discomfort. The treatment is also applied in addressing chronic vaginal dryness and burning associated with VVA.

Regulatory References

1. European Medicines Agency summary

Official Population Eligibility for Biosteron

The use of Prasterone vaginal inserts is strictly defined by regulatory eligibility criteria, limiting its prescription to postmenopausal women only. It is explicitly not indicated for use in female children, adolescents, or women of child-bearing age, nor is it recommended during pregnancy or breastfeeding.

Populations for whom use is Contraindicated (Must Not Use):

• Women with undiagnosed abnormal genital bleeding.
• Women with known, suspected, or a history of breast cancer or other oestrogen-dependent malignant tumours (e.g., endometrial cancer).
• Patients with untreated endometrial hyperplasia or acute liver disease.
• Individuals with hypersensitivity to the active ingredient, Prasterone.

Conditional Use and Special Considerations:

While generally permitted for use in elderly patients, and those with renal or non-acute hepatic impairment, the medicine requires close medical supervision for specific pre-existing conditions. These include a history of endometrial hyperplasia, the presence of Leiomyoma (uterine fibroids) or Endometriosis, and patients with existing risk factors for thromboembolic disorders.

The regulatory information for Biosteron (Prasterone) establishes a clear restriction concerning co-administration with other hormone-containing products, while documenting the absence of other common types of drug interactions.

Official Co-administration Restrictions

The core interaction profile is structured by a pharmacodynamic constraint related to the medicine's conversion into estrogens and androgens at the site of administration. For this reason, co-administration with other hormone therapies is formally restricted in regulatory documents:

• Systemic Hormone Replacement Therapy (HRT): Concomitant use with systemic hormone replacement therapies, which include oestrogen-only, oestrogen-progestogen combinations, or androgen treatments, is not recommended according to official documentation.
• Vaginal Oestrogens: The concurrent use of Biosteron with other localized hormonal products, such as vaginal oestrogens, is also not recommended.

This restriction is based on the lack of clinical investigation into the safety and efficacy of combining Biosteron with these other specific hormonal treatments.

Metabolic and Substance Interactions

The regulatory prescribing information does not document established, clinically significant pharmacokinetic interactions.

• No clinically relevant interactions mediated by the cytochrome P450 (CYP) enzymes or drug transporters are listed in the official label.
• The product has no known interactions with food or drinks, and no mandatory timing separation rules are specified for administration relative to meals or other products.
• The interaction profile does not include any specific restrictions related to the consumption of alcohol or the use of herbal supplements.

Intracrinology: The Localized Prohormone Mechanism

The mechanism of Prasterone (Dehydroepiandrosterone, DHEA) is defined by intracrinology, a process where the inactive drug acts as a prohormone selectively absorbed by target cells. Once inside, specialized steroidogenic enzymes convert it locally into both active Estrogens (like Estradiol) and Androgens (like Testosterone/DHT). This enzymatic conversion localizes the generation and consumption of active hormones at the site of action, resulting in minimal systemic hormonal exposure.

Dual Hormonal Activation and Tissue Structure

The active metabolites function as indirect full agonists at their respective Estrogen ( ER) and Androgen ( AR) nuclear receptors, triggering genomic effects that alter gene transcription. This dual hormonal signaling results in a complementary effect: the Estrogen pathway promotes the maturation and thickness of the epithelial surface, while the Androgen pathway influences the structural elements and integrity of the underlying tissue layers. This cascade results in specific physiological changes, including modified cell proliferation, increased collagen content, and modulation of supporting vascularity within the tissue.

Biosteron is administered as a fixed-dose 6.5 mg vaginal insert intended exclusively for the vaginal route of administration. The official dosing regimen specifies the use of one insert once daily, typically administered at bedtime to maintain consistent local action.

Administration Protocol

The treatment is designed for ongoing, long-term use to manage chronic symptoms, necessitating a periodic clinical re-evaluation by a healthcare professional at least every six months to assess the continued requirement for therapy.

Instruction	Detail
Route of administration	Vaginal (Intravaginal, Local)
Dosing schedule	One 6.5 mg vaginal insert.
Frequency and Timing	Once daily, generally at bedtime.
Missed-dose rule	Skip the dose if the next application is due in less than 8 hours; do not use two inserts to compensate.

Procedural Requirements

For proper use, the administration involves specific preparatory steps: the user should wash their hands and empty their bladder before handling the insert. The insert is administered into the vagina using either the provided single-use applicator or a clean finger, but it must never be taken orally.

Population Considerations: No dose adjustment is specified for elderly women or patients with renal or hepatic impairment, as the administration is designed to be local.

Research evidence / Overview of studies for Biosteron

Evidence for Use in Vulvar and Vaginal Atrophy (VVA) Symptoms

The evidence submitted to health authorities included short-term (12-week) Randomized, Double-Blind, Placebo-Controlled Trials (RCTs). These trials were evaluated in postmenopausal women. Research examined the product compared to an inactive insert, using painful intercourse (dyspareunia) as a primary measurement of outcomes related to physical discomfort.

The short-term studies report how symptoms evolved in the observed populations during the 12-week period. These findings describe patterns observed in the studies by reporting measured changes in the patient-reported severity of dyspareunia. Research was studied for its ability to provide context on symptom patterns observed during the study period.

Research on Objective Markers of Vaginal Tissue

In addition to the patient-reported outcomes, the core research also examined objective measures related to the underlying vaginal tissue. These measurements were collected in all trial participants to evaluate potential shifts in objective markers.

These outcomes related to tissue and cell characteristics included studies monitoring the level of acidity (vaginal pH) and the specific makeup of cells (parabasal and superficial cells) in the vaginal lining. Studies reported measurements of both patient-reported outcomes and objective markers for comparison during the study period.

Long-Term Follow-up and Intermediate-Term Observation

To explore data over a longer duration, researchers conducted an intermediate-term 52-week open-label study. However, controlled follow-up durations were limited, and the consistency of outcomes over intermediate-term periods is assessed using the uncontrolled data. The 52-week study was observed in a single group and did not include a placebo group for comparison for the full duration, which means direct long-term comparison against an inactive insert is not available.

What Research Gaps and Uncertainties Remain

The current body of research mainly consists of studies that was studied for a direct comparison against a placebo or inactive insert. A key research limitation is that comparative evidence is lacking regarding concurrent evaluation against other established VVA therapies. The available research explored symptom patterns over 12 weeks; however, long-term effects are not fully established with controlled data beyond the initial period.

Common questions about Biosteron (FAQ)

Q: How quickly should someone expect Biosteron to start working?

The main clinical studies that assessed this medicine examined changes in symptoms after 12 weeks of daily use. Researchers also noted that symptom improvement continued to be observed during a subsequent 52-week extension study.

Q: Is Biosteron known to cause weight changes?

According to official regulatory documents, weight increase is classified as a common side effect. This means it was observed in a frequency of 1/100 to < 1/10 of users during clinical trials.

Q: Are there any long-term effects of taking Biosteron that are described in the research?

Research included an intermediate-term 52-week open-label study which showed that symptom improvement continued past the initial 12-week findings. Regulatory guidance requires that continued use of the therapy be re-evaluated by a healthcare professional at least every six months.

Q: Does Biosteron interact with common pain relievers like ibuprofen or acetaminophen?

Official regulatory prescribing information does not document established, clinically significant pharmacokinetic interactions mediated by common drug metabolism systems. This refers to how the drug is processed by the body and is often a concern with oral medications.

Q: Why do official sources state Biosteron is not suitable for children?

The official population eligibility criteria strictly define the medicine's use for postmenopausal women only. Use is explicitly restricted for female children, adolescents, and women of child-bearing age because of the medicine’s mechanism as a local hormonal precursor.

Q: If I have kidney or liver issues, can I still take Biosteron?

Acute liver disease is a strict contraindication for this medicine. However, official information notes that no dose adjustment is typically specified for patients with non-acute renal or hepatic impairment, as the administration is designed to be local.

Q: How does Biosteron compare to older treatments for the same condition?

Official research documentation indicates that comparative evidence is lacking regarding concurrent evaluation against other established therapies for vulvar and vaginal atrophy symptoms.

Q: Is it normal to feel [vague common symptom, e.g., tired] when starting Biosteron?

The list of adverse reactions that are classified as very common or common in official regulatory documents does not include general tiredness or fatigue.

Q: Does Biosteron have to be taken at a specific time of day?

The official dosing schedule specifies using the insert once daily, and it is generally described as administered at bedtime. This timing is intended to support consistent local action throughout the 24-hour period.

Q: Are there any restrictions on driving or operating machinery while on Biosteron?

Official prescribing information does not list specific restrictions on driving or operating machinery for users of Biosteron.

Q: Is Biosteron available over-the-counter in any country?

Biosteron (Prasterone vaginal insert) is defined by regulatory agencies as a pharmaceutical preparation. It is approved as a prescription medicine only by bodies like the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Q: Can Biosteron be split or crushed if swallowing is difficult?

The medicine is formulated as a single, fixed-dose vaginal insert designed exclusively for the vaginal route of administration. The insert is designed only for the vaginal route and is not intended for oral use.

Q: Why is Biosteron sometimes described as a 'long-term' medication?

The treatment is designed for ongoing, long-term use to manage chronic symptoms. For this reason, official guidance requires a healthcare professional to re-evaluate the continued requirement for therapy at least every six months.

Q: Is Biosteron known to interact with other prescription medications frequently?

The regulatory prescribing information details restrictions only for co-administration with other hormone-containing products. It specifically notes that other common metabolic and pharmacokinetic interactions are not documented.

Q: Are there any specific lifestyle changes that official documents suggest while taking Biosteron?

Official regulatory documents do not list or suggest specific lifestyle changes (beyond administration protocol) for users taking Biosteron.

Q: Do studies suggest Biosteron is better taken with or without food?

The official label states that the product has no known interactions with food or drinks. Because the medicine is administered locally, there are no mandatory timing rules specified in relation to meals or other products.

Q: What should users know about the risk of overdose with Biosteron?

The official guidance on dosage is strict: the recommended dose is one insert once daily. The official missed-dose guidance states that users should not use two inserts to compensate for a forgotten dose.

Q: What is the role of Biosteron in a comprehensive treatment plan for its indicated use?

Biosteron is indicated as a therapeutic option for the treatment of moderate to severe painful intercourse (dyspareunia), a symptom associated with postmenopausal vulvar and vaginal atrophy. Its use requires periodic clinical re-evaluation by a professional to determine continued need.

Q: Is it possible for Biosteron to cause dizziness?

Dizziness is not classified as a very common or common side effect in the official regulatory documents.

Q: Is Biosteron considered a treatment or a supplement?

Biosteron is defined by regulatory agencies as a pharmaceutical preparation containing a single, purified active ingredient. It is approved as a prescription drug for the treatment of moderate to severe painful intercourse associated with menopause.

Q: Why is Biosteron sometimes compared to [similar drug name]? What's the difference?

The medicine's mechanism is defined by intracrinology, where the active hormones are generated and consumed locally within the cells of the administered tissue. This local action is a key difference noted in regulatory documentation compared to systemic hormonal therapies.

Q: Are there any common foods or drinks that should be avoided while taking Biosteron?

The official regulatory documentation indicates that there are no known interactions with food or drinks associated with taking the medicine.

Q: What are the known issues with taking Biosteron with alcohol (informational query)?

The product's regulatory interaction profile does not include any specific restrictions related to the consumption of alcohol.

Q: Can Biosteron interact with herbal supplements like St. John's Wort?

The product's regulatory interaction profile does not include any specific restrictions related to the use of herbal supplements.

Q: Does Biosteron affect birth control pills?

Official regulatory documents state that concurrent use is not recommended with other hormone therapies. This includes systemic hormone replacement therapies, due to the potential for additive hormonal effects.

Q: Can Biosteron be taken during pregnancy, according to official guidelines?

The medicine is explicitly not indicated and not recommended for use during pregnancy. Its use is restricted only to postmenopausal women.

Q: What is the general success rate mentioned in the clinical studies for Biosteron?

Clinical studies primarily measured change in the patient-reported severity of painful intercourse (dyspareunia). Findings describe measured improvements in symptom patterns and in objective markers of vaginal tissue health over the 12-week study duration.

Q: How long has Biosteron been approved for use by regulatory bodies?

The medicine was first approved by the U.S. Food and Drug Administration (FDA) on November 17, 2016. Other global regulatory bodies have since reviewed and approved the medicine.

How to Store and Dispose of Biosteron?

The storage and disposal instructions for Biosteron are established by official regulatory authorities to ensure product stability and patient safety.

Official Storage Requirements

Condition	Requirement
Temperature	Store below 25 C.
Protection	Keep in the original packaging to protect the product from light and moisture.
Child Safety	Keep this medicine strictly out of the reach and sight of children.
Handling	Maintain the integrity of the original container until use.

Official Disposal Rules

To protect the environment, the medicine should not be disposed of in wastewater or ordinary household garbage. Official regulations require the product to be returned to a pharmacy or disposed of through established local pharmaceutical waste management programs.